Rice's Baker Institute has done it again. Courtesy of Rice University

Furthering its reputation as a world-class educational and intellectual hallmark, Rice University has ascended to the top of yet another ranking.
The school's Baker Institute for Public Policy has been named the No. 1 think tank in the world, according to the 2020 Global Go To Think Tank Index Report published January 28. This is a leap from No. 2 overall last year.

Additionally, its Center for Energy Studies (CES) was again named the top energy and resource policy think tank and was recognized as a Center of Excellence for being ranked No. 1 for three consecutive years, per a press release.

Rice's Baker Institute is also ranked No. 15 out of 110 of the top think tanks in the U.S. overall. It is also listed among the best think tanks globally in the category "Best Quality Assurance and Integrity Policies and Procedures."

Also on the prestigious list are the London School of Economics and Political Science (No. 2) and Institute of Development Studies at the University of Sussex, U.K. (No. 3).

Meanwhile, CES is followed in the regular rankings by the Oxford Institute for Energy Studies, U.K., and the Institute of Energy Economics, Japan.

Founded in 1993, the Baker Institute houses fellows and scholars who conduct research on domestic and foreign policy issues. Core fields of study include energy, the Middle East, Mexico, health policy, public finance, private entrepreneurship and economic growth, international economics, presidential elections, science and technology, China, space policy, and drug policy, according to the school.

CES was founded in October 2012 and provides policymakers, corporate leaders, and the public with quality, data-driven analysis of issues that influence energy markets, per Rice. The Baker Institute Energy Forum is considered an integral part of CES by the university.

"The rise of the Baker Institute and our Center for Energy Studies to the very top rankings in this year's Global Go To Think Tank Index is the culmination of what we created over a quarter of a century ago and of our adherence to excellence in data-driven, nonpartisan research and policy recommendations on public policy issues that reach decision-makers in the private and public sectors," said Baker Institute director Edward Djerejian, in a statement. "I commend all our fellows, scholars and staff, as well as our Board of Advisors and Roundtable members, for this outstanding achievement."

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”